<!doctype html><html class=no-js lang=en><head><meta charset=UTF-8><meta name=viewport content="width=device-width,initial-scale=1"><title>重磅！司美减重适应症国内获批，最火「减肥针」真的来了！ - 文字轨迹</title>
<script>(function(e,t){e[t]=e[t].replace("no-js","js")})(document.documentElement,"className")</script><meta name=description content><meta property="og:url" content="https://ixxmu.github.io/posts/2024-06/%E9%87%8D%E7%A3%85_%E5%8F%B8%E7%BE%8E%E5%87%8F%E9%87%8D%E9%80%82%E5%BA%94%E7%97%87%E5%9B%BD%E5%86%85%E8%8E%B7%E6%89%B9_%E6%9C%80%E7%81%AB_%E5%87%8F%E8%82%A5%E9%92%88_%E7%9C%9F%E7%9A%84%E6%9D%A5%E4%BA%86_/"><meta property="og:site_name" content="文字轨迹"><meta property="og:title" content="重磅！司美减重适应症国内获批，最火「减肥针」真的来了！"><meta property="og:description" content="重磅！司美减重适应症国内获批，最火「减肥针」真的来了！ by 丁香园 本文作者：云也"><meta property="og:locale" content="zh_cn"><meta property="og:type" content="article"><meta property="article:section" content="posts"><meta property="article:published_time" content="2024-06-25T11:40:22+00:00"><meta property="article:modified_time" content="2024-06-25T11:40:22+00:00"><meta property="article:tag" content="Fetched"><meta property="article:tag" content="丁香园"><meta itemprop=name content="重磅！司美减重适应症国内获批，最火「减肥针」真的来了！"><meta itemprop=description content="重磅！司美减重适应症国内获批，最火「减肥针」真的来了！ by 丁香园 本文作者：云也"><meta itemprop=datePublished content="2024-06-25T11:40:22+00:00"><meta itemprop=dateModified content="2024-06-25T11:40:22+00:00"><meta itemprop=wordCount content="226"><meta itemprop=keywords content="Fetched,丁香园"><meta name=twitter:card content="summary"><meta name=twitter:title content="重磅！司美减重适应症国内获批，最火「减肥针」真的来了！"><meta name=twitter:description content="重磅！司美减重适应症国内获批，最火「减肥针」真的来了！ by 丁香园 本文作者：云也"><link rel=preconnect href=https://fonts.gstatic.com crossorigin><link rel=dns-prefetch href=//fonts.googleapis.com><link rel=dns-prefetch href=//fonts.gstatic.com><link rel=stylesheet href="https://fonts.googleapis.com/css?family=Open+Sans:400,400i,700"><link rel=stylesheet href=../../../css/style.css><link rel=stylesheet href=../../../css/custom.css><link rel="shortcut icon" href=../../../favicon.ico></head><body class=body><div class="container container--outer"><header class=header><div class="container header__container"><div class=logo><a class=logo__link href=../../../ title=文字轨迹 rel=home><div class="logo__item logo__text"><div class=logo__title>文字轨迹</div><div class=logo__tagline>故事流淌过的地方</div></div></a></div><nav class=menu><button class=menu__btn aria-haspopup=true aria-expanded=false tabindex=0>
<span class=menu__btn-title tabindex=-1>Menu</span></button><ul class=menu__list><li class=menu__item><a class=menu__link href=../../../posts/><span class=menu__text>文章</span></a></li><li class=menu__item><a class=menu__link href=../../../tags/><span class=menu__text>标签</span></a></li><li class=menu__item><a class=menu__link href=../../../about/><span class=menu__text>关于</span></a></li></ul></nav></div></header><div class="wrapper flex"><div class=primary><main class=main role=main><article class=post><header class=post__header><meta name=referrer content="never"><h1 class=post__title>重磅！司美减重适应症国内获批，最火「减肥针」真的来了！</h1><div class="post__meta meta"><div class="meta__item-datetime meta__item"><svg class="meta__icon icon icon-time" width="16" height="14" viewBox="0 0 30 28"><path d="M15 0a14 14 0 110 28 1 1 0 010-28m0 3a3 3 0 100 22 3 3 0 000-22m1 4h-2v8.4l6.8 4.4L22 18l-6-3.8z"/></svg><time class=meta__text datetime=2024-06-25T11:40:22Z>2024-06-25</time></div><div class="meta__item-categories meta__item"><svg class="meta__icon icon icon-category" width="16" height="16" viewBox="0 0 16 16"><path d="m7 2 1 2h8v11H0V2z"/></svg><span class=meta__text><a class=meta__link href=../../../categories/duty/ rel=category>Duty</a></span></div><div class="meta__item-author meta__item"><svg class="meta__icon icon icon-author" width="16" height="16" viewBox="0 0 16 16"><path d="M8 1c2 0 3.5 2 3.5 4.5S10 9 10 9c3 1 4 2 4 6H2c0-4 1-5 4-6 0 0-1.5-1-1.5-3.5S6 1 8 1"/></svg><span class=meta__text>Bloger</span></div></div></header><div class="post__toc toc"><div class=toc__title>Page content</div><div class=toc__menu><nav id=TableOfContents><ul><li><a href=#重磅司美减重适应症国内获批最火减肥针真的来了-by-丁香园>重磅！司美减重适应症国内获批，最火「减肥针」真的来了！ by 丁香园</a></li></ul></nav></div></div><div class="content post__content clearfix"><h2 id=重磅司美减重适应症国内获批最火减肥针真的来了-by-丁香园>重磅！司美减重适应症国内获批，最火「减肥针」真的来了！ by 丁香园</h2><div><section data-mpa-powered-by=yiban.io><span></span><span>本文作者：</span><span>云也</span></section><p><br></p><p><span><strong><span>刚刚，诺和诺德宣布，司美格鲁肽用于长期体重管理在中国获批上市。</span></strong></span><span></span></p><p><span><span><br></span></span></p><section><img data-backh=455 data-backw=578 data-galleryid data-imgfileid=506089784 data-ratio=0.7872093023255814 data-s=300,640 data-src="https://mmbiz.qpic.cn/mmbiz_png/NzKkzoeG5s2ic7RQ69cKYnc7GmxUYLvSxhrpZEdfibOPnw6s20YgQnoIIJibDFAaL3ZMHq8W97icL62PybNXnx9eLw/640?wx_fmt=png&amp;from=appmsg" data-type=png data-w=860 src="https://mmbiz.qpic.cn/mmbiz_png/NzKkzoeG5s2ic7RQ69cKYnc7GmxUYLvSxhrpZEdfibOPnw6s20YgQnoIIJibDFAaL3ZMHq8W97icL62PybNXnx9eLw/640?wx_fmt=png&amp;from=appmsg"></section><p><br></p><p><span></span><span>全球首</span><span>个且目前唯一</span><span>用于长期体重管理的 GLP</span><span>-</span><span>1 </span><span>受体激动剂（GLP-1RA）的</span><span>周制剂，根据其临床试验结果，</span><span>减重效果</span><span>平均 </span><span>17%（</span><span>16</span><span>.8k</span><span>g）</span><span>。</span></p><p><span><br></span></p><p><span><span>以</span><span>「减肥针</span><span>」之名，司美格鲁肽在国内早已火爆</span><span>多年，其减重适应症何时能</span><span>在</span><span>国内获批，</span><span>一直备</span><span>受关注</span><span>。</span></span></p><p><br></p><p><span>此次获批适用人群为：初始 BMI ≥ 30kg/m</span><span>²</span><span>；</span><span>或在 27～</span><span>30kg/m<span>² </span>之间且存在至少一种体重相关合并症的<span>超重和肥胖症患者<span> [1]</span></span></span><span>。</span></p><p><span></span></p><p><span><br></span></p><p><span><strong><strong><strong>1 周 1 针</strong>降糖+减重，以「减肥针」之名火爆全球</strong></strong></span></p><p><span><br></span></p><p><span>无论是看知名度，还是看真金白银，司美格鲁肽都是近几年当之无愧的明星药。</span></p><p><span><br></span></p><section><span>每周 1 针的便捷，加上优秀的减重效果，诺和盈甫一上市便迅速火爆，渐成现象级药物，2022 年甚至一度发生全球性短缺，持续时间逾 1 年。</span></section><section><br></section><p><span>当年的诺和诺德财报写道，糖尿病和肥胖症治疗领域销售增长 29%，至 1564 亿丹麦克朗（约人民币 1648 亿元）；肥胖症治疗领域增长更高达 101%</span><span> [2]</span><span>。</span></p><p><br></p><p><span>这一增长主要由 GLP-1RA 类药物所驱动，仅司美格鲁肽（用于降糖的诺和泰+用于减重的诺和盈）全球销售额已达 109 亿美元，</span><span><strong>成为首个年销售额破百亿的 GLP-1RA 药物。</strong></span></p><p><span><span><br></span></span></p><p><span>在着力解决产能问题之后，</span><span>2023 年，诺和诺德司美格鲁肽收入 1458.11 亿丹麦克朗，</span><span><strong><span>合计 212 亿美元，仅次于药王 K 药的 250.11 亿美元。其中，诺和盈暴涨 407%，达到 46 亿美元。</span></strong></span></p><p><span><span><br></span></span></p><p><strong><span>现象级药物，常带来一个领域的飞升。</span></strong><span>摩根大通去年曾预期，在司美格鲁肽和替尔泊肽「双巨头」的推动下，2030 年这类药的年销售额将超 1000 亿美元。仅仅半年后，BMO Capital Markets 就又把预期推到了 1500 亿美元 <span>[3</span><span>]</span>。</span></p><p><span><br></span></p><section><img data-backh=285.4 data-backw=544.4 data-galleryid data-imgfileid=506089786 data-ratio=0.524074074074074 data-s=300,640 data-src="https://mmbiz.qpic.cn/mmbiz_png/NzKkzoeG5s3V0Obz5MBFd5hmNupD8meElPwJsngPxFCYDHLNvuzJY17GwMotbDgK5MzXJyEVeqqUnJjy0UayjA/640?wx_fmt=png&amp;from=appmsg" data-type=png data-w=1080 src="https://mmbiz.qpic.cn/mmbiz_png/NzKkzoeG5s3V0Obz5MBFd5hmNupD8meElPwJsngPxFCYDHLNvuzJY17GwMotbDgK5MzXJyEVeqqUnJjy0UayjA/640?wx_fmt=png&amp;from=appmsg"></section><section><span>图源：</span><span>参考资料 3</span></section><p><span><br></span></p><p><span>司美格鲁肽属于 GLP-1 受体激动剂（GLP-1RA）类药物。</span><span>GLP-1 是一种肠促胰素，以葡萄糖浓度依赖的方式促进胰岛素分泌，抑制胰高糖素分泌、降低血糖，同时能延缓胃排空从而抑制食欲。</span><br></p><p><br></p><p><span>司美格鲁肽注射液目前有两款产品。</span><span>本次获批的诺和盈在 2021 年 4 月继利拉鲁肽之后，以「超重或肥胖」为适应症获美国 FDA 批准上市，并在同年再获欧盟批准 </span><span>[4]</span><span>。</span></p><p><br></p><p><img data-backh=385.4 data-backw=544.4 data-galleryid data-imgfileid=506089785 data-ratio=0.7071583514099783 data-s=300,640 data-src="https://mmbiz.qpic.cn/mmbiz_png/NzKkzoeG5s13blvMzRPxd0LI5RVdLJw1NrkKTZmiapUKSUKDroed9Cosyntk2GtneByfmTWKh67ib3qlJHic1iaGcw/640?wx_fmt=png&amp;from=appmsg" data-type=png data-w=922 src="https://mmbiz.qpic.cn/mmbiz_png/NzKkzoeG5s13blvMzRPxd0LI5RVdLJw1NrkKTZmiapUKSUKDroed9Cosyntk2GtneByfmTWKh67ib3qlJHic1iaGcw/640?wx_fmt=png&amp;from=appmsg"></p><p><span>美国 FDA 批准司美格鲁肽用于减肥的适应症 图源：参考资料 4</span></p><p><span><br></span></p><p><span>而较早上市的诺和泰则是降糖药，每周 1 次，每次 0.25mg，0.5mg 或 1mg，</span><strong><span>2017 年底在美国上市，2021 年 4 月中国上市，半年后即进入国家医保谈判目录。</span></strong><span></span></p><p><br></p><p><span>在国内，虽然此前一直仅获批用于降糖，依然挡不住</span><span>司美格鲁肽市场迅速扩张的势头。</span><span>2023 年中国司美格鲁肽市场规模为 52 亿元，同比增长 108%。</span><span>分析师预测今年中国司美格鲁肽市场规模将达到 80 亿元</span><span> </span><span>[5</span><span>]</span><span>。</span><br></p><p><span><br></span></p><p><span>2023 年 6 月 3 日，司美格鲁肽在国内终于迈出了上市的步伐，<span>万众瞩目的</span>减重适应症的申请正式获药监局受理。</span><span></span><span>1 </span><span>年后</span><span>，</span><span>诺和盈终于</span><span>获批上市。</span></p><p><span><br></span></p><p><span><br></span></p><p><span><strong>平均减重 17%、多项健康获益，首个长期结果也已公布</strong></span></p><p><br></p><p><span>虽然国内减重适应症刚刚获批，但在临床应用中，诺和盈之名早已为人所熟知。</span></p><p><br></p><p><span>华北某三甲医院内分泌科副主任医师王薇就总要面对求帮开司美格鲁肽减肥的同事和患者：「来诊室求治肥胖的人，很多都会直接问可不可以开司美格鲁肽，知名度超高。被患者和同事追着帮开『减肥针』，一度是工作中的常态。」</span></p><p><br></p><p><strong><span>诺和盈适用于在控制饮食和增加体力活动的基础上对成人患者的长期体重管理，初始 BMI ≥ 30kg/m²；或在 27～30kg/m² 之间且存在至少一种体重相关合并症，</span></strong><span>例如高血糖、</span><span>高血压、血脂异常、阻塞性睡眠呼吸暂停或心血管疾病等 <span>[1</span><span>]</span>。</span></p><p><span><br></span></p><p><strong><span>根据其 Ⅲ 期临床试验，诺和盈可以实现平均 17%（16.8kg）的体重降幅，并带来多重健康获益，</span></strong><span>包括但</span><span>不限于减少腰围、降低内脏脂肪、改善血脂、延缓糖尿病前期进展等。</span><span></span></p><p><br></p><p><span>上个月，诺和诺德公司还在欧洲肥胖大会上公布了持续使用司美格鲁肽 4 年的减重效果数据，研究结果同时也在 </span><em>Nature Medicine</em><span> 在线发表 <span>[6]</span>。</span></p><p><br></p><p><img data-backh=340.4 data-backw=544.4 data-galleryid data-imgfileid=506089789 data-ratio=0.6260162601626016 data-s=300,640 data-src="https://mmbiz.qpic.cn/mmbiz_png/NzKkzoeG5s0wtzSUmsN3FtQUY8Wc8KGcFpfxib1MeZ6DAib3T658JWYiceQxzakgkQ981hiaprMupxYzWy5Dk5IYuA/640?wx_fmt=png&amp;from=appmsg" data-type=png data-w=984 src="https://mmbiz.qpic.cn/mmbiz_png/NzKkzoeG5s0wtzSUmsN3FtQUY8Wc8KGcFpfxib1MeZ6DAib3T658JWYiceQxzakgkQ981hiaprMupxYzWy5Dk5IYuA/640?wx_fmt=png&amp;from=appmsg"></p><p><span>图源：参考资料 6</span></p><p><br></p><p><span>这项试验为 SELECT 多中心、随机、双盲、安慰剂对照研究的一部分</span><span>。</span><span>除 BMI 外，研究人员还检测了体脂组成和分布的指标，包括腰围、腰围-身高比（WHtR），因为中心腹部脂肪与一般肥胖相比，会导致更大的心血管风险。</span></p><p><br></p><p><span><strong><span>结果显示，在诺和盈组，体重减轻持续到第 65 周，并在此基础上维持了 4 年。</span></strong></span><span>患者体重平均减轻了 10.2%，腰围平均减小了 7.7cm。</span><span>而安慰剂组这两个数值分别为 1.5% 和 1.3cm。</span><span></span></p><p><br></p><p><img data-backh=378.4 data-backw=544.4 data-galleryid data-imgfileid=506089791 data-ratio=0.6941694169416942 data-s=300,640 data-src="https://mmbiz.qpic.cn/mmbiz_png/NzKkzoeG5s0wtzSUmsN3FtQUY8Wc8KGcQV1Q5qjcNMfcx9vxPZV1DfEm4156nkxuOsYmj6hib8jJA3tWYSuwqNQ/640?wx_fmt=png&amp;from=appmsg" data-type=png data-w=909 src="https://mmbiz.qpic.cn/mmbiz_png/NzKkzoeG5s0wtzSUmsN3FtQUY8Wc8KGcQV1Q5qjcNMfcx9vxPZV1DfEm4156nkxuOsYmj6hib8jJA3tWYSuwqNQ/640?wx_fmt=png&amp;from=appmsg"></p><p><span>使用司美格鲁肽 4 年的减重曲线 图源：参考资料 6</span></p><p><span><br></span></p><p><strong><span>总而言之，研究证明无论地区、</span></strong><strong><span>种族、体</span></strong><strong><span>型、性别，没有糖尿病的超重或肥胖成年人都可以通过每周 1 针司美格鲁肽，安全、有效地持续减轻体重、减少腰围至少 4 年。</span></strong></p><p><br></p><p><span></span><span>解放军总医院第一医学中心母义明教授在新闻中指出：「</span><span>公众对于肥胖症作为一种慢性复杂疾病及其带来的健康问题认知不足，导致就诊率较低。</span><span>科学的体重管理是为了促进个人的长期健康。</span><span>体重管理不应单以减重为目标，同时应关注代谢益处和远期健康获益。」<span>[1]</span></span></p><p><span><br></span></p><p><em><span><span>Nature</span></span></em><span><span> 曾发文讨论 GLP-1 受体激动剂类药物停药率高的问题，同时指出为了能够长期稳定减重降糖，目前研究人员和临床医师通常将这类药视为一种长期甚至终身治疗</span><span> [7]</span><span>。</span></span></p><p><span><br></span></p><p><span>由于一直缺乏证据，司美格鲁肽减重长效性到底如何，是否会耐受、反弹，一直备受关注。</span><span>这项研究可谓千呼万唤始出来，为临床长期治疗提供了重要参考。</span></p><p><br></p><p><span>另外值得一提的是，同是这次欧洲肥胖大会，诺和诺德还报告了 SELECT 关于使用司美格鲁肽治疗时的基线体重、研究期间体重变化，与心血管结局，包括首次发生主要不良心血管事件 （MACE） 的时间和心力衰竭之间的关系</span><span> <span>[8]</span></span><span>。</span></p><p><br></p><p><span>研究结果表明，无论起始体重和体重减轻多少，司美格鲁肽治疗都能带来心血管益处。</span><strong><span>即使是肥胖程度相对轻微的患者，或者体重减轻并不显著，也可能改善心血管结局。</span></strong></p><p><br></p><p><span>研究者英国伦敦大学学院 John Deanfield 详解了这一结果的重要临床意义：「这一研究结果表明该药降低心血管风险的作用，不完全依赖于减肥，可能是影响血糖、血压、炎症，或对心肌和血管有直接影响。」</span><span><span> </span><span>[9]</span></span></p><p><br></p><p><img data-backh=608.4 data-backw=544.4 data-galleryid data-imgfileid=506089788 data-ratio=1.1183098591549296 data-s=300,640 data-src="https://mmbiz.qpic.cn/mmbiz_png/NzKkzoeG5s0wtzSUmsN3FtQUY8Wc8KGc4MXAedyNcDE9ibHFCxfnhFe4OEpYFeztAuDhlUUeZLhEvmyYiaRmCVHg/640?wx_fmt=png&amp;from=appmsg" data-type=png data-w=710 src="https://mmbiz.qpic.cn/mmbiz_png/NzKkzoeG5s0wtzSUmsN3FtQUY8Wc8KGc4MXAedyNcDE9ibHFCxfnhFe4OEpYFeztAuDhlUUeZLhEvmyYiaRmCVHg/640?wx_fmt=png&amp;from=appmsg"></p><p><span>作者评论研究意义 图源：参考资料 9</span></p><p><br></p><p><strong><span>司美格鲁肽已然是诺和诺德的镇厂之宝，但也就在这烈火烹油的盛况下，全球药企其实都暗中窥伺已久。</span></strong><span>虽然只有诺和诺德原研的司美格鲁肽在售，但凡是有点多肽药物研发能力的企业，都绸缪已久。</span></p><p><span><br></span></p><p><span></span><span>CDE 官网显示，目前进入 Ⅲ 期临床的就不下十家，甚至已有两家已在排队等着上市。</span><strong><span>司美格鲁肽注射液生物类似药体重管理适应症更是当前研发一大热门，</span></strong><span>九源基因、丽珠集团、倍特药业、翰宇药业、特瑞药业等都已经申请了减重适应症的临床试验。</span></p><p><br></p><p><span>终于，国内首个减重适应症的司美格鲁肽，还是留给了原研药。</span></p><p><span><br></span></p><p><span>「减肥针」，真的来了。</span></p><p><span><br></span></p><p><span>策划：</span><span>云也｜监制：</span><span>gyouza、carollero</span></p><section><span>题图来源：视觉中国</span></section><section data-role=outer label="Powered by 135editor.com"><section data-color=#eb6794><section><section><span>参考资料：</span></section><p><span>[1]https://mp.weixin.qq.com/s?__biz=MzkyNzIxOTU0Ng==&amp;mid=2247489397&amp;idx=1&amp;sn=12be3e8231b21436515ff5acdfd451eb&amp;chksm=c22a3d40f55db4564e3b965a3c1fb8cef4622eac2962db0a1c3a420ed70a7755cdebe6751a49&amp;mpshare=1&amp;scene=1&amp;srcid=0625gXguCdzg7rFYTgOJuMKD&amp;sharer_shareinfo=81dd15525e3a9916a56b33d7ff93977a&amp;sharer_shareinfo_first=81dd15525e3a9916a56b33d7ff93977a#rd</span></p><p><span>[2]https://www.novonordisk.com/investors/financial-results.html</span></p><p><span><span>[3]https://www.biospace.com/article/obesity-market-to-reach-150b-as-demand-grows-supply-stabilizes-reuters/</span></span></p><p><span>[4]https://www.fda.gov/news-events/press-announcements/fda-approves-new-drug-treatment-chronic-weight-management-first-2014</span></p><p><span><span>[5]《2023-2029全球与中国长效GLP-1RA市场现状及未来发展趋势》</span></span></p><p><span><span>[6]Ryan, D.H., Lingvay, I., Deanfield, J. et al. Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial. Nat Med (2024). https://doi.org/10.1038/s41591-024-02996-7</span></span></p><p><span><span>[7]<span>https://www.nature.com/articles/d41586-024-01091-8</span></span></span></p><p><span><span><span>[8]<span>https://karger.com/ofa/article-pdf/17/Suppl.%201/7/4225727/000538577.pdf</span></span></span></span></p><p><span><span><span>[9]<span>https://medicalxpress.com/news/2024-05-semaglutide-yield-weight-loss-heart.html</span></span></span></span></p></section></section></section><section><span>丁香园是面向医疗从业者的专业平台，以「助力中国医生」为己任。在丁香园，可以和同行讨论病例 ，在线学习公开课，使用用药助手等临床决策工具，在丁香人才找可靠医疗岗位</span></section><section><span><br></span></section><section><mp-common-profile data-pluginname=mpprofile data-id="MTg0MzMwODA0MQ==" data-headimg="http://mmbiz.qpic.cn/mmbiz_png/NzKkzoeG5s0aWFLyZf1azqKVZziaZZ6odnNVTtibWkciaUibvHB1GWOXlSjaWIcv1zGIB7RIyn9bKFHg4hUvp6fSRg/0?wx_fmt=png" data-nickname=丁香园 data-alias=dingxiangwang data-signature=千万医务工作者的网上家园。我们深知医疗的痛苦与快乐，在丁香园里，您可以了解最新资讯、阅读深度报道，并与同行进行交流。 data-from=0 data-is_biz_ban=0></mp-common-profile></section><section><span></span></section><p><mp-style-type data-value=10000></mp-style-type></p></div><hr><a href=https://mp.weixin.qq.com/s/-IOKvpAtkojJOncnfYgeww ,target=_blank rel="noopener noreferrer">原文链接</a></div><footer class=post__footer><div class="post__tags tags clearfix"><svg class="tags__badge icon icon-tag" width="16" height="16" viewBox="0 0 32 32"><path d="M4 0h8s2 0 4 2l15 15s2 2 0 4L21 31s-2 2-4 0L2 16s-2-2-2-4V3s0-3 4-3m3 10a3 3 0 000-6 3 3 0 000 6"/></svg><ul class=tags__list><li class=tags__item><a class="tags__link btn" href=../../../tags/fetched/ rel=tag>fetched</a></li><li class=tags__item><a class="tags__link btn" href=../../../tags/%E4%B8%81%E9%A6%99%E5%9B%AD/ rel=tag>丁香园</a></li></ul></div></footer></article></main><div class="authorbox clearfix"><div class=authorbox__header><span class=authorbox__name>About Bloger</span></div></div><nav class="pager flex"><div class="pager__item pager__item--prev"><a class=pager__link href=../../../posts/2024-06/%E8%B5%B6%E8%B6%85%E6%B1%9F%E8%8B%8F_%E4%B8%AD%E5%9B%BD%E9%AB%98%E6%A0%A1%E7%AC%AC%E4%B8%80%E7%9C%81_%E6%98%93%E4%B8%BB%E4%BA%86/ rel=prev><span class=pager__subtitle>«&#8201;Previous</span><p class=pager__title>赶超江苏！中国高校第一省，易主了</p></a></div><div class="pager__item pager__item--next"><a class=pager__link href=../../../posts/2024-06/%E8%A1%80%E5%B8%B8%E8%A7%84%E4%B8%AD%E7%9A%84_%E5%8D%95%E6%A0%B8%E7%BB%86%E8%83%9E_%E6%98%AF%E4%BB%80%E4%B9%88_%E6%9C%89%E4%BD%95%E4%B8%B4%E5%BA%8A%E6%84%8F%E4%B9%89_/ rel=next><span class=pager__subtitle>Next&#8201;»</span><p class=pager__title>血常规中的「单核细胞」是什么？有何临床意义？</p></a></div></nav><section class=comments><div id=disqus_thread></div><script>window.disqus_config=function(){},function(){if(["localhost","127.0.0.1"].indexOf(window.location.hostname)!=-1){document.getElementById("disqus_thread").innerHTML="Disqus comments not available by default when the website is previewed locally.";return}var t=document,e=t.createElement("script");e.async=!0,e.src="//kkitown.disqus.com/embed.js",e.setAttribute("data-timestamp",+new Date),(t.head||t.body).appendChild(e)}()</script><noscript>Please enable JavaScript to view the <a href=https://disqus.com/?ref_noscript>comments powered by Disqus.</a></noscript><a href=https://disqus.com class=dsq-brlink>comments powered by <span class=logo-disqus>Disqus</span></a></section></div><aside class=sidebar><div class="widget-search widget"><form class=widget-search__form role=search method=get action=https://google.com/search><input class=widget-search__field type=search placeholder=Search… name=q aria-label=Search…>
<input class=widget-search__submit type=submit value=Search>
<input type=hidden name=sitesearch value=https://ixxmu.github.io/></form></div><div class="widget-recent widget"><h4 class=widget__title>Recent Posts</h4><div class=widget__content><ul class=widget__list><li class=widget__item><a class=widget__link href=../../../posts/2024-09/%E4%B8%80%E4%B8%AAfollow_%E6%90%9E%E5%AE%9A%E4%BD%A0%E6%89%80%E6%9C%89%E7%9A%84%E4%BF%A1%E6%81%AF%E6%BA%90_%E5%8C%BA%E5%9D%97%E9%93%BE_ai_%E6%89%93%E9%80%A0%E7%9B%AE%E5%89%8D%E6%9C%80%E5%BC%BA%E5%A4%A7%E7%9A%84_rss_%E4%BF%A1%E6%81%AF%E6%95%B4%E5%90%88%E5%B7%A5%E5%85%B7/>一个Follow，搞定你所有的信息源！区块链+AI，打造目前最强大的 RSS 信息整合工具</a></li><li class=widget__item><a class=widget__link href=../../../posts/2024-09/%E8%BD%B0%E5%8A%A8%E4%B8%80%E6%97%B6%E7%9A%84_%E8%87%AD%E6%B0%A7%E5%B1%82%E7%A9%BA%E6%B4%9E_%E7%8E%B0%E5%9C%A8%E5%88%B0%E5%BA%95%E6%80%8E%E4%B9%88%E6%A0%B7%E4%BA%86_/>轰动一时的“臭氧层空洞”现在到底怎么样了？</a></li><li class=widget__item><a class=widget__link href=../../../posts/2024-09/%E6%B2%B3%E5%8D%97%E6%9F%90%E5%9C%B0%E5%86%9C%E6%B0%91%E7%94%9F%E6%B4%BB%E4%B8%BE%E4%BE%8B__%E6%89%93%E7%83%9F%E5%8F%B6/>河南某地农民生活举例——打烟叶</a></li><li class=widget__item><a class=widget__link href=../../../posts/2024-09/positron_%E4%B8%8B%E4%B8%80%E4%BB%A3r%E5%92%8Cpython%E6%95%B0%E6%8D%AE%E5%88%86%E6%9E%90ide/>Positron：下一代R和python数据分析IDE</a></li><li class=widget__item><a class=widget__link href=../../../posts/2024-09/%E6%9C%80%E6%96%B0%E6%95%B0%E6%8D%AE%E5%87%BA%E6%9D%A5%E4%BA%86_%E6%8E%A5%E4%B8%8B%E6%9D%A5_%E5%8F%AA%E8%83%BD%E9%9D%A0%E8%87%AA%E5%B7%B1%E4%BA%86_/>最新数据出来了，接下来，只能靠自己了！</a></li></ul></div></div><div class="widget-categories widget"><h4 class=widget__title>Categories</h4><div class=widget__content><ul class=widget__list><li class=widget__item><a class=widget__link href=../../../categories/duty/>Duty</a></li><li class=widget__item><a class=widget__link href=../../../categories/duty2/>Duty2</a></li></ul></div></div><div class="widget-taglist widget"><h4 class=widget__title>Tags</h4><div class=widget__content><a class="widget-taglist__link widget__link btn" href=../../../tags/cnbeta/ title=Cnbeta>Cnbeta (33)</a>
<a class="widget-taglist__link widget__link btn" href=../../../tags/fetched/ title=Fetched>Fetched (461)</a>
<a class="widget-taglist__link widget__link btn" href=../../../tags/githubdaily/ title=GitHubDaily>GitHubDaily (7)</a>
<a class="widget-taglist__link widget__link btn" href=../../../tags/%E4%B8%81%E9%A6%99%E5%9B%AD/ title=丁香园>丁香园 (24)</a>
<a class="widget-taglist__link widget__link btn" href=../../../tags/%E4%BA%BA%E7%89%A9/ title=人物>人物 (6)</a>
<a class="widget-taglist__link widget__link btn" href=../../../tags/%E5%8D%97%E6%96%B9%E5%91%A8%E6%9C%AB/ title=南方周末>南方周末 (9)</a>
<a class="widget-taglist__link widget__link btn" href=../../../tags/%E5%B0%8F%E4%BC%97%E8%BD%AF%E4%BB%B6/ title=小众软件>小众软件 (5)</a>
<a class="widget-taglist__link widget__link btn" href=../../../tags/%E5%B0%8F%E5%A4%A7%E5%A4%AB%E6%BC%AB%E7%94%BB/ title=小大夫漫画>小大夫漫画 (5)</a>
<a class="widget-taglist__link widget__link btn" href=../../../tags/%E5%B0%91%E6%95%B0%E6%B4%BE/ title=少数派>少数派 (6)</a>
<a class="widget-taglist__link widget__link btn" href=../../../tags/%E6%98%9F%E7%90%83%E5%95%86%E4%B8%9A%E8%AF%84%E8%AE%BA/ title=星球商业评论>星球商业评论 (5)</a>
<a class="widget-taglist__link widget__link btn" href=../../../tags/%E7%81%BC%E8%A7%81/ title=灼见>灼见 (5)</a>
<a class="widget-taglist__link widget__link btn" href=../../../tags/%E7%94%9F%E4%BF%A1%E6%8A%80%E8%83%BD%E6%A0%91/ title=生信技能树>生信技能树 (9)</a>
<a class="widget-taglist__link widget__link btn" href=../../../tags/%E7%9F%A5%E8%AF%86%E5%88%86%E5%AD%90/ title=知识分子>知识分子 (8)</a>
<a class="widget-taglist__link widget__link btn" href=../../../tags/%E7%BD%91%E6%98%93%E6%95%B0%E8%AF%BB/ title=网易数读>网易数读 (5)</a>
<a class="widget-taglist__link widget__link btn" href=../../../tags/%E8%B4%A2%E7%BB%8F%E4%B8%89%E5%88%86%E9%92%9F/ title=财经三分钟>财经三分钟 (6)</a>
<a class="widget-taglist__link widget__link btn" href=../../../tags/%E9%83%91%E5%B7%9E%E6%A5%BC%E5%B8%82/ title=郑州楼市>郑州楼市 (30)</a></div><a href=../../../tags/></a></div><div class="widget-social widget"><h4 class="widget-social__title widget__title">Social</h4><div class="widget-social__content widget__content"><div class="widget-social__item widget__item"><a class="widget-social__link widget__link btn" title=Facebook rel="noopener noreferrer" href=https://facebook.com/username target=_blank><svg class="widget-social__link-icon icon icon-facebook" width="24" height="24" viewBox="0 0 352 352"><path d="m0 32v288c0 17.5 14.5 32 32 32h288c17.5.0 32-14.5 32-32V32c0-17.5-14.5-32-32-32H32C14.5.0.0 14.5.0 32zm320 0v288h-83V212h41.5l6-48H237v-31c0-14 3.5-23.5 23.5-23.5h26V66c-4.4-.6-19.8-1.5-37.5-1.5-36.9.0-62 22.2-62 63.5v36h-42v48h42v108H32V32z"/></svg>
<span>Facebook</span></a></div><div class="widget-social__item widget__item"><a class="widget-social__link widget__link btn" title=Twitter rel="noopener noreferrer" href=https://twitter.com/username target=_blank><svg class="widget-social__link-icon icon icon-twitter" width="24" height="24" viewBox="0 0 384 312"><path d="m384 36.9c-14.1 6.3-29.3 10.5-45.2 12.4 16.3-9.7 28.8-25.2 34.6-43.6-15.2 9-32.1 15.6-50 19.1-14.4-15.2-34.9-24.8-57.5-24.8-43.5.0-78.8 35.3-78.8 78.8.0 6.2.7 12.2 2 17.9-65.5-3.3-123.5-34.6-162.4-82.3C20 26 16.1 39.6 16.1 54c0 27.3 13.9 51.4 35 65.6-12.9-.4-25.1-4-35.7-9.9v1c0 38.2 27.2 70 63.2 77.2-6.6 1.8-13.6 2.8-20.8 2.8-5.1.0-10-.5-14.8-1.4 10 31.3 39.1 54.1 73.6 54.7-27 21.1-60.9 33.7-97.8 33.7-6.4.0-12.6-.4-18.8-1.1C34.9 299 76.3 312 120.8 312c144.9.0 224.1-120 224.1-224.1.0-3.4-.1-6.8-.2-10.2 15.4-11.1 28.7-25 39.3-40.8z"/></svg>
<span>Twitter</span></a></div><div class="widget-social__item widget__item"><a class="widget-social__link widget__link btn" title=Instagram rel="noopener noreferrer" href=https://www.instagram.com/username target=_blank><svg class="widget-social__link-icon icon icon-instagram" width="24" height="24" viewBox="0 0 256 256"><circle cx="193" cy="59" r="15"/><path fill-rule="evenodd" d="M101 0h54c41 0 58.4 3.9 74.5 17C256.2 37.5 256 74.8 256 97.7v60c0 26.7.0 60.4-26.5 81.4-16 13.4-33.5 16.9-74.5 16.9h-54c-41 0-57.5-3.5-74.5-16.9C1 218.9.5 186.3.1 160.5L0 155V97.7c0-23-.2-60.2 26.5-80.7C45 2 60 0 101 0zm4.9 23h44.3c45.8.0 58.3 3.5 70.3 17.5 11.8 13.2 12 30.1 12.5 62.9V156c.2 20.8.3 45.8-12.5 59.5-12 14-24.5 17.5-70.3 17.5h-44.3c-45.9.0-57.3-3.5-70.4-17.5-12.2-13-12.3-36.5-12.4-56.7v-55.6c.4-32.6.7-49.6 12.4-62.7C48 26.5 60 23 105.9 23zm19.6 144.5a42 42 0 100-84 42 42 0 000 84zm0 22.5a64.5 64.5.0 100-129 64.5 64.5.0 000 129z"/></svg>
<span>Instagram</span></a></div></div></div></aside></div><footer class=footer><div class="container footer__container flex"><div class=footer__copyright>&copy; 2024 文字轨迹.
<span class=footer__copyright-credits>Generated with <a href=https://gohugo.io/ rel="nofollow noopener" target=_blank>Hugo</a> and <a href=https://github.com/Vimux/Mainroad/ rel="nofollow noopener" target=_blank>Mainroad</a> theme.</span></div></div></footer></div><script async defer src=../../../js/menu.js></script><script src=../../../js/custom.js></script><script src="https://cdnjs.cloudflare.com/ajax/libs/mathjax/2.7.6/MathJax.js?config=TeX-AMS-MML_HTMLorMML" async></script></body></html>